Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: Long-term results from the Bio-CAPTURE registry

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 3, 2015, Pages 560-565

  Van Den Reek, J M P A ^a   Tummers, M ^a   Zweegers, J ^a   Seyger, M M B ^a   Van Lumig P P M ^a   Driessen, R J B ^a   Van De Kerkhof, P C M ^a   Kievit, W ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMORBIDITY; DISEASE REGISTRY; FEMALE; HUMAN; LONG TERM CARE; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSORIASIS; PSORIASIS VULGARIS; REIMBURSEMENT; SURVIVAL; SURVIVAL RATE; PROSPECTIVE STUDY;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS;

EID: 84923104729     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12636     Document Type: Article

References (27)

1. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-188.
2. Rustin MH,. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (Suppl 3): 3-11.
3. Burden AD,. Drug survival rates for tumour necrosis factor-alpha antagonists in psoriasis. Br J Dermatol 2011; 164: 940-941.
4. Rustenbach SJ, Heyer K, Reppenhagen K, Augustin M,. Registry research in dermatology. Hautarzt 2011; 62: 189-195.
5. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
6. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
7. Aletaha D,. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis research & therapy. 2009; 11 (3): 112. Epub 2009/06/13.
8. Brunasso AM, Puntoni M, Massone C,. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 2012; 166: 447-449.
9. Esposito M, Gisondi P, Cassano N,. et al. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study. Br J Dermatol 2013; 169 (3): 666-672.
10. Lopez-Ferrer A, Vilarrasa E, Gich IJ, Puig L,. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single spanish centre. Br J Dermatol 2013; 169: 1141-1147.
11. Yeung H, Wan J, Van Voorhees AS, et al,. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 64-72.
12. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA,. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-374.
13. Feldman SR, Evans C, Russell MW,. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005; 16: 37-42.
14. Nast A, Boehncke WH, Mrowietz U,. et al. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10 Suppl 2; S1-S95.
15. Zweegers J, de Jong EM, Nijsten TE, de Bes J, te Booij M, Bogonjen RJ, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatology online journal. 2014; 20 (3): Epub 2014/03/25.
16. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
17. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ,. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713.
18. Saad AA, Ashcroft DM, Watson KD, et al,. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
19. Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C,. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63: 228-234.
20. Cassano N, Galluccio A, De Simone C, et al,. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents 2008; 22: 233-237.
21. Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN,. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-1397.
22. Ortonne JP, Chimenti S, Reich K, et al,. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011; 25: 1012-1020.
23. Papoutsaki M, Chimenti MS, Costanzo A, et al,. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
24. Van L, Modi SV, Yang DJ, Hsu S,. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008; 144: 804-806.
25. van Lumig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM,. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Acad Dermatol Venereol 2013; 27: 593-600.
26. Yamauchi PS, Mau N,. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol 2009; 61: 158-160.
27. Glintborg B, Ostergaard M, Dreyer L, et al,. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-390.